AN + AD for cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL

Released: December 17, 2022

Expiration: December 16, 2023

Activity

Progress
1
Course Completed